News Daily News Increased CVD Risk Seen Up to 30 Years Before Type 2 Diabetes Diagnosis Todd Neale November 28, 2024
News Conference News AHA 2024 GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes Michael O'Riordan November 17, 2024
News Conference News AHA 2024 SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity Michael O'Riordan November 16, 2024
News Conference News AHA 2024 Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD Yael L. Maxwell November 16, 2024
News Daily News Rural Counties Bore Brunt of Worsening CV Mortality During Pandemic Yael L. Maxwell November 15, 2024
News Daily News Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data Michael O'Riordan November 07, 2024
News Daily News SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients L.A. McKeown October 23, 2024
News Daily News Time-Restricted Eating Tightens Glycemic Control in Patients With Metabolic Syndrome Caitlin E. Cox October 04, 2024
News Daily News Cramming Weekly Physical Activity Into 1 or 2 Days Still Yields Benefits Michael O'Riordan October 03, 2024
News Conference News HFSA 2024 Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity Todd Neale October 01, 2024
News Daily News Medicaid Coverage Improves CV Risk in Some, Post Hoc Analysis Shows Todd Neale September 25, 2024
News Conference News ESC 2024 FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients Michael O'Riordan September 01, 2024
News Conference News ESC 2024 Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery Todd Neale August 30, 2024
News Daily News ‘Disproportionate’ Suicide/Self-Harm Signal With Semaglutide: WHO Database Michael O'Riordan August 21, 2024
News Daily News Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes Michael O'Riordan August 19, 2024
News Daily News Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors Yael L. Maxwell August 15, 2024